NCT06545682 2026-04-16
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
32 trialsNCT05508906 2025-10-22
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 1 Recruiting
NCT05143229 2025-10-06
ASSET
University of Kansas Medical Center
Phase 1 Active not recruiting
NCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting
NCT01870505 2024-12-09
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03207529 2024-10-10
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03631953 2024-08-06
ALTREM
Assistance Publique Hopitaux De Marseille
Phase 1 Recruiting
NCT01791478 2024-07-23
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Active not recruiting
NCT01300962 2023-12-04
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT02273219 2023-08-15
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Columbia University
Phase 1 Completed
NCT05472220 2022-12-27
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
University of California, San Francisco
Phase 1 Withdrawn
NCT02734615 2022-08-01
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Novartis
Phase 1 Terminated
NCT02282371 2021-10-26
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02167854 2021-07-09
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02537223 2021-04-19
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
University Health Network, Toronto
Phase 1 Completed
NCT02155088 2021-04-08
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02550743 2021-03-12
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
Brown University
Phase 1 Terminated
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01735968 2020-12-21
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Novartis
Phase 1 Completed
NCT01822613 2020-12-19
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Novartis
Phase 1 Completed
NCT02088684 2020-12-17
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT02144038 2020-12-17
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
Novartis
Phase 1 Completed
NCT01613950 2020-12-09
PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
Novartis
Phase 1 Completed
NCT01928459 2020-12-09
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Novartis
Phase 1 Completed
NCT01387321 2020-12-08
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies
Novartis
Phase 1 Completed
NCT02051751 2020-12-08
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Novartis
Phase 1 Completed
NCT02077933 2020-12-08
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis
Phase 1 Completed
NCT01219699 2020-09-22
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
Novartis
Phase 1 Completed
NCT02038010 2020-06-29
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
Northwestern University
Phase 1 Completed
NCT02058381 2020-03-09
B-YOND
Novartis
Phase 1 Completed
NCT02620839 2020-01-10
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
University of California, San Francisco
Phase 1 Terminated
NCT01449058 2017-10-02
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Array BioPharma
Phase 1 Completed